Bupropion-SR

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49